ALLO
NASDAQ · Biotechnology
Allogene Therapeutics Inc
$2.28
+0.01 (+0.44%)
Open$2.29
Previous Close$2.27
Day High$2.36
Day Low$2.25
52W High$4.46
52W Low$0.86
Volume—
Avg Volume6.08M
Market Cap752.00M
P/E Ratio—
EPS$-0.87
SectorBiotechnology
Analyst Ratings
Strong Buy
21 analysts
Price Target
+865.4% upside
Current
$2.28
$2.28
Target
$22.01
$22.01
$17.29
$22.01 avg
$30.07
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 52.71M | 52.93M | 41.75M |
| Net Income | 7.77M | 8.17M | 5.40M |
| Profit Margin | 14.7% | 15.4% | 12.9% |
| EBITDA | 12.72M | 14.19M | 11.69M |
| Free Cash Flow | 7.78M | 12.29M | 5.60M |
| Rev Growth | +19.4% | -7.3% | -1.4% |
| Debt/Equity | 1.42 | 1.47 | 1.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |